Latest On Cocrystal Pharma, Inc (COCP):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-31 18:34 EST | News | Cocrystal cleared to run Phase 1 trial for COVID-19 drug in Australia | N/A |  |
| 2023-05-15 22:25 EST | News | Cocrystal Pharma GAAP EPS of -$0.64 misses by $0.05 | N/A | |
| 2023-04-10 20:48 EST | News | Cocrystal Pharma completes $4M equity offering priced ATM | N/A | |
| 2023-03-29 10:52 EST | News | Cocrystal Pharma GAAP EPS of -$4.77 | N/A | |
| 2022-11-15 00:23 EST | News | Cocrystal Pharma GAAP EPS of -$0.70 misses by $0.21 | N/A | |
About Cocrystal Pharma, Inc (COCP):
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discov read more...er and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX, Inc. The company is headquartered in Bothell, Washington.
General
- Name Cocrystal Pharma, Inc
- Symbol COCP
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 11
- Last Split Factor1:30
- Last Split Date2018-01-24
- Fiscal Year EndDecember
- IPO Date2011-05-19
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.cocrystalpharma.com
Valuation
- Price/Sales (Trailing 12 Mt.) 39.86
- Price/Book (Most Recent Quarter) 2.34
- Enterprise Value Revenue 42.74
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.17
- Next Quarter EPS Estimate -$0.04
- Operating Margin -476%
- Return on Assets -14%
- Return on Equity -25%
- Revenue 2.01 million
- Earnings Per Share -$1.47
- Revenue Per Share $0.04
- Gross Profit 2.01 million
- Quarterly Earnings Growth 26.9%
Highlights
- Market Capitalization 107.92 million
- EBITDA -3424000
- Analyst Target Price $4.75
- Book Value Per Share $0.75
Share Statistics
- Shares Outstanding 71.47 million
- Shares Float 47.6 million
- % Held by Insiders 2904%
- % Held by Institutions 23.76%
- Shares Short 2.21 million
- Shares Short Prior Month 2.21 million
- Short Ratio 0.79
- Short % of Float 4%
- Short % of Shares Outstanding 3%
Technicals
- Beta 0.91
- 52 Week High $2.48
- 52 Week Low $0.6
- 50 Day Moving Average 1.76
- 200 Day Moving Average 1.34
Dividends
- Dividend Date 2018-01-24
- ExDividend Date N/A
- Dividend Yield 0%
Cocrystal Pharma, Inc (COCP) Dividend Calendar:
COCP's last dividend payment was made to shareholders on January 24, 2018.
Cocrystal Pharma, Inc (COCP) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Cocrystal Pharma, Inc (COCP) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Cocrystal Pharma, Inc (COCP) Chart:
Cocrystal Pharma, Inc (COCP) News:
Below you will find a list of latest news for Cocrystal Pharma, Inc (COCP) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Cocrystal Pharma, Inc (COCP) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest COCP Trades:
Cocrystal Pharma, Inc (COCP) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | 8-K (Current report) | |
| 2020-10-02 | 8-K (Current report) | |
| 2020-08-27 | 8-K (Current report) | |
| 2020-08-27 | 8-K (Current report) | |
| 2020-08-27 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-08-27 | 8-K (Current report) | |
| 2020-08-26 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-08-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-02 | 8-K (Current report) | |
| 2020-07-02 | 8-K (Current report) | |
| 2020-07-01 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-06-26 | 8-K (Current report) | |
| 2020-06-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-15 | 8-K (Current report) | |